NASDAQ:OMER Omeros (OMER) Stock Price, News & Analysis $5.22 -0.06 (-1.14%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.09▼$5.4150-Day Range$3.29▼$5.4752-Week Range$0.92▼$5.68Volume244,435 shsAverage Volume331,431 shsMarket Capitalization$302.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Omeros alerts: Email Address Omeros MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish23.27% of Float Sold ShortDividend StrengthN/ASustainability-1.30Upright™ Environmental ScoreNews Sentiment0.51Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.36 out of 5 starsMedical Sector906th out of 936 stocksPharmaceutical Preparations Industry425th out of 436 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Omeros.Read more about Omeros' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted23.27% of the float of Omeros has been sold short.Short Interest Ratio / Days to CoverOmeros has a short interest ratio ("days to cover") of 38.6, which indicates bearish sentiment.Change versus previous monthShort interest in Omeros has recently increased by 0.39%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOmeros does not currently pay a dividend.Dividend GrowthOmeros does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOmeros has received a 67.78% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Omeros is -1.30. Previous Next 2.5 News and Social Media Coverage News SentimentOmeros has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Omeros this week, compared to 2 articles on an average week.MarketBeat Follows8 people have added Omeros to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Omeros insiders have not sold or bought any company stock.Percentage Held by Insiders10.90% of the stock of Omeros is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions48.79% of the stock of Omeros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Omeros' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Omeros is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Omeros is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Omeros' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Omeros Stock (NASDAQ:OMER)Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Read More OMER Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OMER Stock News HeadlinesJuly 25 at 9:44 PM | finance.yahoo.comOmeros Corporation (OMER)July 25 at 1:19 AM | americanbankingnews.comInvestors Purchase High Volume of Omeros Put Options (NASDAQ:OMER)July 27, 2024 | DTI (Ad)How to build the ultimate dividend portfolioThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again.July 19, 2024 | seekingalpha.comOmeros: Troubled Company Working Its Way Out Of The MorassJuly 19, 2024 | americanbankingnews.comOmeros (NASDAQ:OMER) Rating Increased to Hold at StockNews.comJune 4, 2024 | businesswire.comOmeros Announces Webcast Details for Annual Meeting of ShareholdersJune 3, 2024 | businesswire.comOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028May 19, 2024 | marketwatch.comOmeros Shares Drop 20% After Wider 1Q LossJuly 27, 2024 | DTI (Ad)How to build the ultimate dividend portfolioThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again.May 16, 2024 | msn.comOmeros Corporation (NASDAQ:OMER) Q1 2024 Earnings Call TranscriptMay 16, 2024 | msn.comOmeros plunges 20% following Q1 report, drug updateMay 16, 2024 | finance.yahoo.comQ1 2024 Omeros Corp Earnings CallMay 16, 2024 | finance.yahoo.comOmeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ...May 15, 2024 | investorplace.comOMER Stock Earnings: Omeros Misses EPS for Q1 2024May 15, 2024 | businesswire.comOmeros Corporation Reports First Quarter 2024 Financial ResultsMay 14, 2024 | msn.comOmeros Q1 2024 Earnings PreviewMay 10, 2024 | businesswire.comOmeros Corporation to Announce First Quarter Financial Results on May 15, 2024May 9, 2024 | finance.yahoo.comOmeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid CongressSee More Headlines Receive OMER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/27/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OMER CUSIP68214310 CIK1285819 Webwww.omeros.com Phone(206) 676-5000Fax206-676-5005Employees210Year Founded1994Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,916.35% Return on Assets-39.01% Debt Debt-to-Equity RatioN/A Current Ratio4.76 Quick Ratio4.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-13.05Miscellaneous Outstanding Shares57,940,000Free Float51,628,000Market Cap$302.45 million OptionableOptionable Beta1.46 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Gregory A. Demopulos M.D. (Age 65)Co-Founder, Chairman, CEO & President Comp: $1.79MMr. Michael A. Jacobsen (Age 66)Chief Accounting Officer, VP of Finance & Treasurer Comp: $518.6kMr. Peter B. Cancelmo J.D. (Age 45)VP, General Counsel & Corporate Secretary Comp: $503.24kDr. Pamela Pierce Palmer M.D. (Age 61)Ph.D., Co-Founder Dr. George A. Gaitanaris M.D. (Age 67)Ph.D., Chief Scientific Officer & VP of Science Mr. Peter W. Williams (Age 56)Vice President of Human Resources Dr. Catherine A. Melfi Ph.D. (Age 65)Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems Ms. Nadia Dac (Age 54)VP & Chief Commercial Officer Dr. Andreas Grauer M.D. (Age 63)VP & Chief Medical Officer More ExecutivesKey CompetitorsVanda PharmaceuticalsNASDAQ:VNDAEsperion TherapeuticsNASDAQ:ESPRRadius RecyclingNASDAQ:RDUSCara TherapeuticsNASDAQ:CARAPhibro Animal HealthNASDAQ:PAHCView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 31,081 shares on 7/26/2024Ownership: 0.377%Cypress Capital GroupBought 10,000 shares on 7/25/2024Ownership: 0.060%Virtu Financial LLCSold 18,983 shares on 5/20/2024Ownership: 0.017%Comerica BankBought 5,000 shares on 5/17/2024Ownership: 0.052%Vanguard Group Inc.Bought 81,348 shares on 5/10/2024Ownership: 5.610%View All Insider TransactionsView All Institutional Transactions OMER Stock Analysis - Frequently Asked Questions How have OMER shares performed this year? Omeros' stock was trading at $3.27 at the beginning of 2024. Since then, OMER stock has increased by 59.6% and is now trading at $5.22. View the best growth stocks for 2024 here. How were Omeros' earnings last quarter? Omeros Co. (NASDAQ:OMER) released its quarterly earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.13. What is Gregory A. Demopulos' approval rating as Omeros' CEO? 17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees. Does Omeros have any subsidiaries? The following companies are subsidiaries of Omeros: Nura. Who are Omeros' major shareholders? Omeros' top institutional investors include Bank of New York Mellon Corp (0.38%) and Cypress Capital Group (0.06%). Insiders that own company stock include Peter A Md Demopulos, Gregory A Md Demopulos and Arnold C Hanish. View institutional ownership trends. How do I buy shares of Omeros? Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Omeros own? Based on aggregate information from My MarketBeat watchlists, some other companies that Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Technologies (ARRY), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Alibaba Group (BABA) and Sangamo Therapeutics (SGMO). This page (NASDAQ:OMER) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
